Ensayos clínicos

Inclusion Criteria:

• Must have the ability to understand and sign a written ICF, which must be obtained prior to initiation of study procedures associated with this trial.
• Must have enrolled in a CD parent protocol, GS-US-419- 4015, GS-US-419-4016 or GS-US-419-3895.
• Females of childbearing potential must have a negative pregnancy test at Day 1 and must agree to continued monthly pregnancy testing during use of filgotinib treatment.
• Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 6, for the duration described.
• Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose of study drug.
• Must have completed all required procedures or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study for CD.

Exclusion Criteria:

• Subjects who are discontinued from a parent study for reasons other than disease worsening, or lack of response or remission; e.g., subjects who discontinue for safety or tolerability issues are not eligible for the present study.
• Known hypersensitivity to the study drug.
• Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease, alcohol or drug abuse) that, in the opinion of the Investigator or Sponsor, would make the subject unsuitable for the study or would prevent compliance with the study protocol.
• Females who may wish to become pregnant and/or plan to undergo egg donation or egg harvesting for the purpose of current or future fertilization during the course of the study and for at least 35 days of the last dose of the study drug.
• Male subjects unwilling to refrain from sperm donation for at least 90 days after the last dose of study drug.
• Males or females of reproductive potential who are unwilling to abide by protocol-specified contraceptive methods as defined in Appendix 6.
• Use of prohibited concomitant medications as outlined in Section 5.4.2.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/16/23. Questions regarding updates should be directed to the study team contact.